As the coming year approaches, more vendors are working toward meeting Stage 2 meaningful use in electronic health record (EHR) products.
As the coming year approaches, more vendors are working toward meeting Stage 2 meaningful use in electronic health record (EHR) products.
“It has been a slow start. They’re working hard. They’re struggling a little bit,” said Alisa Ray, executive director and CEO of the Certification Commission for Health Information Technology, CCHIT. She adds that when comparing Stage 1 with Stage 2 certification, vendors are “navigating a higher bar and increased complexity.”
The 3 areas that have been most challenging in achieving Stage 2 certification are clinical quality measures, interoperability, and automated measure calculation for reporting metrics. Ms Ray reports that while more than 2000 products are being certified, only around 20% have been completely processed through the requirements. “It’s a testament to how much harder it is,” she said.
With the head seat of the Office of the National Coordinator for Health Information Technology vacant, and with a worrisome timetable for vendors to meet Stage 2 requirements, some are considering the possibility of a delay in implementation.
“Stage 2 definitely ups the ante, and the 2014 requirements are pretty significant. I think a lot of vendors are trying to also develop things in parallel to keep up with different payment models, and ACOs, and different initiatives like ICD-10,”says Lauren Fifield, senior health policy advisor at Practice Fusion. “They’re trying to develop data analytics platforms and things like that. So I’m not terribly surprised. Come January or February, I think it’ll be more of a tell-tale sign.”
However, federal requirements to meet Stage 2 meaningful use in EHRs is an intelligent move for the healthcare industry—the more stringent benchmarks for providers and vendors will drive value and quality.
Around the Web
EHR MakersSurprised by Stage 2 Complexity [Government Health IT]
EHR Market in Flux as Stage 2 of Meaningful Use Approaches [EHR Intelligence]
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Managed Care Reflections: A Q&A With David J. Shulkin, MD
July 7th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The July issue features a conversation with David J. Shulkin, MD, a physician and former secretary of the US Department of Veterans Affairs.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More